Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LHC165 alone or with PDR001 in advanced solid tumors
NCT03301896Phase 1Terminated
- Sponsor
- Novartis
- Start
- Jan 2018
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of LHC165 in solid tumor, sponsored by Novartis. Primary endpoint: Incidence of Dose-limiting Toxicities at 28 days. Started Jan 2018; status: terminated.
02
Drugs
LHC165
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03301896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03301896.